HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of low molecular weight procyanidin rich extract from french maritime pine bark on cardiovascular disease risk factors in stage-1 hypertensive subjects: Randomized, double-blind, crossover, placebo-controlled intervention trial.

AbstractBACKGROUND:
Oligopinۚ (OP) is a quantified extract from French Maritime Pine bark (FMPB) with low molecular weight procyanidins. The cardioprotective effects of OP need to be tested in human clinical intervention trials with an appropriate design.
PURPOSE:
The aim of the present study was to assess the effect of subchronic consumption of OP on cardiovascular disease risk factors such as lipid profile, systolic blood pressure (BP) and oxidized-Low Density Lipoprotein (ox-LDL) in stage-1-hypertensive subjects.
METHODS:
Between February 14 and May 31, 2014, eligible subjects were recruited from the outpatient clinics of Hospital Universitari Sant Joan (Reus, Spain). A total of 24 participants (mean age ± DS; 57.36 ± 11.25; 17 men) with stage-1-hypertension who were not receiving BP-lowering medication and LDL cholesterol < 4.88 mmol/l were randomized in a double-blind, placebo-controlled, crossover study. The subjects received 2 capsules/day with 75 mg of OP or placebo for 5-weeks.
RESULTS:
At 5-weeks, compared to the placebo, OP raised High Density Lipoprotein-cholesterol (HDL-c) by 14.06% (p = 0.012) and apolipoprotein A-1 by 8.12% (p = 0.038) and reduced the ratio of apolipoprotein B-100/A-1 by 10.26% (p = 0.046). Moreover, at 5-weeks, compared to the baseline, OP reduced the systolic BP by 6.36 mmHg (p = 0.014), and decreased ox-LDL concentrations by 31.72 U/l (p = 0.015).
CONCLUSION:
At 5-weeks, the consumption of 150 mg/day of OP improve lipid cardiovascular profile and represents one of the scarce ways to increase HDL-c in stage-1-hypertensive subjects.
TRIAL REGISTRATION:
ClinicalTrials.gov: NCT02063477.
AuthorsRosa-M Valls, Elisabet Llauradó, Sara Fernández-Castillejo, Francesc Puiggrós, Rosa Solà, Lluis Arola, Anna Pedret
JournalPhytomedicine : international journal of phytotherapy and phytopharmacology (Phytomedicine) Vol. 23 Issue 12 Pg. 1451-1461 (Nov 15 2016) ISSN: 1618-095X [Electronic] Germany
PMID27765365 (Publication Type: Journal Article, Randomized Controlled Trial)
CopyrightCopyright © 2016. Published by Elsevier GmbH.
Chemical References
  • Apolipoprotein A-I
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Lipids
  • Lipoproteins, LDL
  • Oligopin
  • Plant Extracts
  • Polyphenols
  • Proanthocyanidins
  • oxidized low density lipoprotein
Topics
  • Aged
  • Apolipoprotein A-I (blood)
  • Blood Pressure (drug effects)
  • Cardiovascular Diseases (blood, etiology)
  • Cholesterol, HDL (blood)
  • Cholesterol, LDL (blood)
  • Cross-Over Studies
  • Double-Blind Method
  • Humans
  • Hypertension (blood, drug therapy)
  • Lipids (blood)
  • Lipoproteins, LDL (blood)
  • Male
  • Middle Aged
  • Molecular Weight
  • Phytotherapy
  • Pinus (chemistry)
  • Plant Bark (chemistry)
  • Plant Extracts (pharmacology, therapeutic use)
  • Polyphenols (pharmacology, therapeutic use)
  • Proanthocyanidins (pharmacology, therapeutic use)
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: